Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

C.C. Fong, Peter; S. Boss, David; A. Yap, Timothy; Tutt, Andrew; Wu, Peijun; Mergui‐Roelvink, Marja; G. Mortimer, Peter; Swaisland, Helen; Lau, Alan; J. O’Connor, Mark; Ashworth, Alan; Carmichael, James; B. Kaye, Stan; H.M. Schellens, Jan; S. de Bono, Johann

doi:10.1056/nejmoa0900212

Public

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Published in New England Journal of Medicine • Jun 24, 2009

Authors:

Peter C.C. Fong

David S. Boss

Timothy A. Yap

Abstract

BACKGROUND: The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation. We conducted a clinical evalu...

Subject

Olaparib

Medicine

PARP inhibitor

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!